DXCM Share Price Performance

US$74.22

-8.78 (-10.58%)

US$83.42

Fair Value

US$74.22

-8.78 (-10.58%)

11.0% undervalued

US$83.42

Fair Value

US$74.22

US$83.42

US$65.00

Tue, 9 Jun 26

Fair ValueUS$83.42

Share Pricen/a

DXCM Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$83.42 11.0% undervalued

DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty

AnalystLowTarget's

Fair Value

Fair Value US$65 14.2% overvalued

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook

About DXCM

Founded: 1999
Employees: 11050
CEO: Jacob Leach
WebsiteView website: www.dexcom.com

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Recent DXCM News & Updates

Announcement • 7h

Dexcom Inc Clears First Over-The-Counter Continuous Glucose Monitor For Children

Dexcom Inc.'s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin, was cleared for marketing as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children. The FDA previously cleared the Stelo Glucose Biosensor System OTC for individuals 18 years and older in March 2024. Prediabetes is increasingly impacting children in the United States, placing millions at heightened risk for progressing to Type 2 diabetes. OTC CGMs can play a critical role in addressing this public health concern for pediatric users who do not use insulin. By providing real-time glucose data, these devices can help pediatric patients and their caregivers build greater glycemic awareness, track patterns in response to meals and exercise, and make informed adjustments to support healthier long-term outcomes and quality of life. The product is indicated for children, including those with diabetes, who receive oral medication to manage their condition and people who want to understand how diet, exercise, and other lifestyle changes affect their glucose levels. The Stelo Glucose Biosensor System uses a wearable sensor, paired with an application installed on a compatible smartphone, or other smart device, such as a parent's or caregiver's smartphone, to continuously measure, record, analyze and display glucose values. Each sensor lasts for up to 15 days before it must be replaced, although sensor wear time may be shorter in pediatric users than in adults due to several interconnected physiological and behavioral factors. The app displays glucose measurements and trends every 15 minutes. Users and their caregivers should consult their health care provider before making any medication adjustments based on the device's output. Dexcom and the FDA used previous clinical study data from both pediatrics and adults, along with real-world evidence derived from real-world data on current iCGM use among both groups, to understand expected device performance in pediatric users over the full 15-day wear period. Participants in the previous study reported mild adverse events including local infection, skin irritation, and pain or discomfort. For children, the device should be used under the supervision of an adult caregiver. This system is not for people with problematic hypoglycemia (low blood sugar) because it is not designed to alert users when this potentially dangerous condition occurs. This system is also not for people on dialysis. People with a history of disordered eating or eating disorders should talk with their health care provider before using Stelo. This clearance is also aligned with the FDA's Home as a Health Care Hub Initiative, which focuses on advancing the development of innovative, patient-centered devices that fit more seamlessly into people's daily lives at home.

Recent updates

No updates

DexCom, Inc. Stock Price

DXCM Share Price Performance

DXCM Community Narratives

DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook

DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook

Trending Discussion

Recently Updated Narratives

DXCM: CONNECT Data And Digital Health Expansion Will Shape Balanced Future Outlook

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook

Snowflake Analysis

DexCom, Inc. Key Details

About DXCM

Recent DXCM News & Updates

Dexcom Inc Clears First Over-The-Counter Continuous Glucose Monitor For Children

DexCom Expands Type 2 Diabetes Reach With G7 Data Nutrisense Acquisition and Stelo App Plans

DXCM: CONNECT Data And Digital Health Expansion Will Shape Balanced Future Outlook

Recent updates

DexCom, Inc. Competitors

Abbott Laboratories

Intuitive Surgical

CVS Health

Stryker